NASDAQ : NEO

NeoGenomics, Inc.

$13.14 USD

-$0.75 (-5.4%)

Volume
1.72M
Average Volume
2.73M
Market Capitalization
$342.2M
P/E Ratio
-3.43
Dividend Yield
0.00%
Price Target
$19.00
Year High
$15.57
Year Low
$4.72
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$4.42
Company Overview

NASDAQ

Anthony Zook

Medical - Diagnostics & Research

Healthcare

NEO

2500

US

USD

https://www.neogenomics.com

239 768 0600

64049M209

0001077183

Liquidity Metrics

0.49

4.42

4.06

1.73

0.00

Sales & Valuation

$727.33M

0.46

0.41

-67.26

-0.20

Profitability

-$4.2

-$108.02M

-13.30%

-13.70%

-11.82%

-7.37%

P/E Metrics

-3.43

0.11

0.11

Analyst Price Target & Rating

$19.00

$25.00

$13.00

Sell

2/5

29 Analysts

-30.84%

Financial Health Scores

0.52

4/9

$289.09M

$1.35B

$517.77M

-$100.06M

Key Metrics (TTM)

$624.11M

0.84

-18.60

4.42

-11.82%

-7.97%

-27.65%

-1.41%

85 days

Company Executives
Name Title
Kendra Sweeney Vice President of Investor Relations & Communications
Andrew A. Lukowiak Chief Innovation Officer
Anthony Zook Chief Executive Officer & Director
Gary Passman Chief People & Culture Officer
Warren Stone President & Chief Operating Officer
Alicia Olivo Executive Vice President of Business Development, General Counsel & Corporate Secretary
Clarence Cooper Vice President of Compliance & Privacy
Elizabeth A. Floegel Chief Digital & Information Officer
Abhishek Jain Executive VP & CFO
Gregory D. Aunan Senior Vice President & Chief Accounting Officer
Kareem Saad Head of Strategy, Business Development & Transformation
Poll Results

No votes yet today — be the first to share your view!

About NeoGenomics, Inc. (NASDAQ:NEO) Stock

NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Addition ... ally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

2026-07-23 08:15:25

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

2026-07-21 07:57:01

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

2026-07-20 17:23:00

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS.

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

2026-07-15 09:00:00

CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the chemistry, manufacturing and controls (“CMC”) development program for NEO212, the Company's novel temozolomide-perillyl alcohol conjugate.

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

2026-07-09 07:05:00

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.

NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

2026-07-07 07:05:00

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

2026-06-25 07:05:00

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

2026-06-23 09:00:00

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company's lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery.

Frequently Asked Questions

What is the current NeoGenomics, Inc. (NEO) stock price?

NeoGenomics, Inc.(NASDAQ:NEO) stock price is $13.14 in the last trading session. During the trading session, NEO stock reached the peak price of $15.57 while $4.72 was the lowest point it dropped to. The percentage change in NEO stock occurred in the recent session was --5.4% while the dollar amount for the price change in NEO stock was -$0.75.

NEO's industry and sector of operation?

The NASDAQ listed NEO is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of NEO?

Kendra Sweeney | Vice President of Investor Relations & Communications
Andrew A. Lukowiak | Chief Innovation Officer
Anthony Zook | Chief Executive Officer & Director
Gary Passman | Chief People & Culture Officer
Warren Stone | President & Chief Operating Officer

How many employees does NEO have?

Number of NEO employees currently stands at 2500. NEO operates from 9490 NeoGenomics Way, Fort Myers, FL 33912, US.

Link for NEO official website?

Official Website of NEO is: https://www.neogenomics.com

How do I contact NEO?

NEO could be contacted at phone #239 768 0600 and can also be accessed through its website. NEO operates from 9490 NeoGenomics Way, Fort Myers, FL 33912, US.

How many shares of NEO are traded daily?

The average number of NEO shares traded daily for last 3 months was 2.73M.

What is the market cap of NEO currently?

The market value of NEO currently stands at $342.2M with its latest stock price at $13.14